L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
Non-Hodgkin Lymphoma
Explore 373 assets in Non-Hodgkin Lymphoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Nektar Therapeutics
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05664217CT.gov NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | — | Terminated | — | — | — |
NCT04136756CT.gov NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) (this asset) | Nektar Therapeutics | P2/3 | CCC · 53 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2/3 | CCC · 53 |
| Lung Cancer | — | P2 | CC · 47 |
| Indolent B-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-methionyl-interleukin-15-human-non-glycosylated-produced-in-escherichia-coli-substituted-on-an-average-of-one-site-among-n2-of-met1-andor-n6-of-lysyl-residues-with-4-alpha-methylpolyoxyethylene-omega-oxybutanoyl-groups-40-kda-each-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →